The CEO of Hungarian pharmaceutical company Richter reiterated 2024 guidance on Tuesday after it reported higher ...

AbbVie is currently addressing serious health ... 30% from Western Europe, Canada, Japan and Australia and 40% from the fastest-growing economies, including India, China, Russia and Brazil.

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and recent operational highlights for the third quarter ended September 30, 2024.

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

U.S. stocks rose Monday, led by those seen as benefiting the most from Donald Trump’s reelection as president, but drops for ...

His uber-bullish prediction, which would represent a 66% surge by 2030, is another sign that Wall Street is growing ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

AbbVie’s Aquipta has become the first once ... Aquipta, known as Qulipta in the US and Canada, is the first daily oral treatment for both chronic and episodic migraines and, according to ...

Some of the sharpest swings were in the crypto market, where bitcoin rose above US$82,000 for the first time. Trump has ...

ARS Pharmaceuticals shares jumped Monday after the company inked a deal to commercialize its allergic reaction nasal spray internationally.

BMO Capital analyst Evan Seigerman lowered the firm’s price target on AbbVie (ABBV) to $208 from $228 and keeps an Outperform rating on ...